Eculizumab (Soliris) and biosimilars coverage
Customize your policy alerts
Sign up for Centene Policy CP PHAR.97 alerts
Get alerted when Policy CP PHAR.97 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and dosing criteria for Soliris and its biosimilars (eculizumab-aeeb, eculizumab-aagh) across indications including PNH, aHUS, gMG, and NMOSD for Centene lines of business.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.